Health Trials

Clinical trials

14

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke

This phase II clinical study is designed to evaluate the efficacy and safety of LT3001 in the treatment of acute ischemic stroke

Participants needed: 300
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Shanghai Pharmaceuticals Holding Co., LtdUpdated: Aug 10, 2026Locations: 1
Eligibility criteria

Clinical diagnosis of acute ischemic stroke that causes evaluable neurological i... [+4]

Participants have received or plan to receive endovascular treatment and/or intr... [+23]

Read more
Status: Recruiting

A Clinical Study of T3011 in Subjects With Advanced Melanoma

This clinical study evaluated the tolerability, safety and preliminary efficacy of T3011 in subjects with advanced melanoma.

Participants needed: 42
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Pharmaceuticals Holding Co., LtdUpdated: Aug 6, 2026Locations: 7
Eligibility criteria

Subjects with advanced melanoma; [+7]

Subjects who have received other antitumor therapy within the prescribed time pr... [+12]

Read more
Status: Recruiting

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.

Participants needed: 63
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Pharmaceuticals Holding Co., LtdUpdated: Aug 6, 2026Locations: 16
Eligibility criteria

Subjects voluntarily participate in this study and sign informed consent. [+6]

Taking anti-tumor traditional Chinese medicines at the time of signing the ICF. [+11]

Read more
Status: Recruiting

A Clinical Study of SPH9788 Tablets in Healthy Chinese Subjects.

The purpose of the study is to evaluate the safety of SPH9788 tablets in healthy subjects.

Participants needed: 94
Trial details
Phase: Phase 1Age: 18-45Biological sex: AllType: InterventionalSponsor: Shanghai Pharmaceuticals Holding Co., LtdUpdated: May 5, 2026Locations: 1
Eligibility criteria

Healthy male and female subjects aged from 18 to 45 years; [+4]

Medical history (current or past) that in the investigator's judgment may interf... [+11]

Read more
Status: Recruiting

A Clinical Study of SPH7854 Granules in Healthy Subjects.

To evaluate the safety of SPH7854 in healthy subjects.

Participants needed: 111
Trial details
Phase: Early Phase 1Age: 18-45Biological sex: AllType: InterventionalSponsor: Shanghai Pharmaceuticals Holding Co., LtdUpdated: May 5, 2026Locations: 1
Eligibility criteria

Volunteer to participate in clinical research; Fully understand and know the stu... [+3]

Female subjects who are breastfeeding or have positive pregnancy results; [+5]

Read more
Status: Recruiting

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1 inhibitors in subjects with advanced solid tumors

Participants needed: 68
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Pharmaceuticals Holding Co., LtdUpdated: May 5, 2026Locations: 22
Eligibility criteria

Subjects with advanced solid tumors; [+7]

Subjects who have received other antitumor therapy within the prescribed time pr... [+12]

Read more
Status: Recruiting

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.

Participants needed: 52
Trial details
Phase: Phase 2Age: 18-75Biological sex: FemaleType: InterventionalSponsor: Shanghai Pharmaceuticals Holding Co., LtdUpdated: May 5, 2026Locations: 25
Eligibility criteria

Patients who voluntarily participate in this study, completely understand this s... [+6]

Inflammatory breast cancer. [+14]

Read more
Status: Recruiting

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke

Participants needed: 300
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Shanghai Pharmaceuticals Holding Co., LtdUpdated: Apr 30, 2026Locations: 28
Eligibility criteria

Subjects aged between 18 and 80 years at screening; [+1]

Subjects have received or plan to receive endovascular treatment and/or intraven... [+22]

Read more
Status: Recruiting

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

To evaluate the safety and tolerability of SPH5030 tablets in subjects with HER2-positive advanced solid tumors

Participants needed: 150
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Pharmaceuticals Holding Co., LtdUpdated: May 5, 2026Locations: 17
Eligibility criteria

ECOG performance status of 0 to 1. [+5]

Subjects who have received the prescribed treatment at the prescribed time prior... [+16]

Read more
Status: Recruiting

Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)

The objectives of this phase Ib study are to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenic profiles of B001 in subjects with aquaporin-4 antibody (AQP4-IgG) positive NMOSD.

Participants needed: 45
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Pharmaceuticals Holding Co., LtdUpdated: May 5, 2026Locations: 4
Eligibility criteria

NMOSD as defined by either of the following 2015 criteria with anti-AQP4 antibod... [+3]

Any previous treatment with anti-CD20, eculizumab, anti-BLyS monoclonal antibody... [+15]

Read more
Status: Recruiting

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in the treatment of locally advanced or metastatic breast cancer that progressed on CDK4/6 inhibitor combined with endocrine therapy.

Participants needed: 254
Trial details
Phase: Phase 2, Phase 3Age: 18-75Biological sex: FemaleType: InterventionalSponsor: Shanghai Pharmaceuticals Holding Co., LtdUpdated: Jan 14, 2026Locations: 22
Eligibility criteria

Patients who voluntarily participate in this study, completely understand this s... [+6]

Inflammatory breast cancer. [+15]

Read more
Status: Recruiting

A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.

To evaluate the efficacy and safety of SPH7485 tablets in patients with advanced solid tumors.

Participants needed: 170
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Pharmaceuticals Holding Co., LtdUpdated: Aug 17, 2025Locations: 6
Eligibility criteria

Histologically or cytologically confirmed advanced solid tumors； [+7]

Subjects who have received the prescribed other anti-tumor treatments at the pre... [+21]

Read more
Status: Recruiting

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer.

Participants needed: 60
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Pharmaceuticals Holding Co., LtdUpdated: Aug 17, 2025Locations: 30
Eligibility criteria

Metastatic and/or unresectable advanced colorectal adenocarcinoma, or locally ad... [+7]

Subjects who have previously received anti-HER2 molecular targeted therapy; [+2]

Read more
Status: Recruiting

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

This study is designed to evaluate the safety and efficacy of SPH4336 combined with letrozole in first-line treatment of locally advanced or metastatic breast cancer

Participants needed: 374
Trial details
Phase: Phase 2, Phase 3Age: 18-75Biological sex: FemaleType: InterventionalSponsor: Shanghai Pharmaceuticals Holding Co., LtdUpdated: Aug 17, 2025Locations: 9
Eligibility criteria

Patients who voluntarily participate in the study, completely understand the stu... [+8]

Prior treatment with any CDK4/6 （Cyclin dependent kinase）inhibitor. [+17]

Read more